|2.18||+0.0700||+3.32%||Vol 3.77M||1Y Perf -67.93%|
|Nov 29th, 2023 16:00 DELAYED|
|- -||0.02 0.88%|
|Target Price||17.25||Analyst Rating||Moderate Buy 1.67|
|Potential %||691.28||Finscreener Ranking||★★ 45.47|
|Insiders Trans % 3/6/12 mo.||-/-/-100||Value Ranking||☆ 32.27|
|Insiders Value % 3/6/12 mo.||-/-/-100||Growth Ranking||★ 39.26|
|Insiders Shares Cnt. % 3/6/12 mo.||-/-/-100||Income Ranking||— -|
|Price Range Ratio 52W %||7.84||Earnings Rating||Strong Buy|
|Market Cap||242.77M||Earnings Date||6th Nov 2023|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Sell|
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|12/2024 FY||-0.72||-2 500.00||Negative|
|Next Report Date||-|
|Estimated EPS Next Report||-0.45|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||2.47M|
|Avg. Monthly Volume||6.74M|
|Avg. Quarterly Volume||4.13M|
Coherus BioSciences Inc. (NASDAQ: CHRS) stock closed at 2.18 per share at the end of the most recent trading day (a 3.32% change compared to the prior day closing price) with a volume of 3.77M shares and market capitalization of 242.77M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 317 people. Coherus BioSciences Inc. CEO is Dennis M. Lanfear.
The one-year performance of Coherus BioSciences Inc. stock is -67.93%, while year-to-date (YTD) performance is -72.47%. CHRS stock has a five-year performance of -80.29%. Its 52-week range is between 1.4301 and 10.9907, which gives CHRS stock a 52-week price range ratio of 7.84%
Coherus BioSciences Inc. currently has a PE ratio of -2.70, a price-to-book (PB) ratio of 73.19, a price-to-sale (PS) ratio of 4.22, a price to cashflow ratio of 20.10, a PEG ratio of 3.59, a ROA of -47.25%, a ROC of -53.53% and a ROE of -4 085.49%. The company’s profit margin is -99.13%, its EBITDA margin is -103.00%, and its revenue ttm is $165.69 Million , which makes it $2.13 revenue per share.
Of the last four earnings reports from Coherus BioSciences Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.45 for the next earnings report. Coherus BioSciences Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Coherus BioSciences Inc. is Moderate Buy (1.67), with a target price of $17.25, which is +691.28% compared to the current price. The earnings rating for Coherus BioSciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Coherus BioSciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Coherus BioSciences Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 10.44, ATR14 : 0.30, CCI20 : -38.40, Chaikin Money Flow : -0.19, MACD : -0.37, Money Flow Index : 36.53, ROC : 3.94, RSI : 41.46, STOCH (14,3) : 48.57, STOCH RSI : 1.00, UO : 48.41, Williams %R : -51.43), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Coherus BioSciences Inc. in the last 12-months were: Lanfear Dennis (Option Excercise at a value of $425 915), Lanfear Dennis (Sold 223 100 shares of value $450 662 )
Tue, 26 Sep 2023 10:11 GMT Analysts Are Bullish on Top Healthcare Stocks: Coherus Biosciences (CHRS), Qiagen (QGEN)- TipRanks. All rights reserved.
Mon, 07 Aug 2023 02:27 GMT Coherus Biosciences (CHRS) Gets a Buy from Truist Financial- TipRanks. All rights reserved.
Copyright © 2016-2023 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
General partner of Finscreener is SLOVAKODATA, a.s.
This could take some time, please wait.